Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer | MicrobiomeTrials← Back to trialsNCT04243616
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2020-03-05Est. Completion: 2025-08-11
Enrollment target: 36 participants Locations- Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Researchers are looking for new ways to treat types of breast cancer that are both:
* High-risk, which means the cancer…
Gilbert, United StatesEst. completion Mar 23, 2033
Metastatic Invasive Breast CancerResistant Breast CancerER+, HER2-, Metastatic Breast Cancer
The goal of this clinical trial is to learn if neratinib, an FDA-approved oral pan-HER2/3/4 inhibitor, improves disease …
La Jolla, United StatesEst. completion May 2032